Condition: Non-clear Renal Cell Carcinoma · Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The goal of this prospective, multicenter, single-arm clinical study is to evaluate the efficacy and safety of toripalimab in combination with axitinib for postoperative adjuvant therapy for non-clear renal cell carcinoma with high-risk recurrence factors.
This description comes directly from the study's public registry record.
shun zhang · 15050589789 · explorershun@126.com
Always discuss trial participation with your own doctor first.
| Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University | Nanjing, Jiangsu, China | Recruiting |
| Hongqian Guo | Nanning, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05768464